Francesco Alesiani - Concepedia

Author

Francesco Alesiani

Azienda Ospedaliero Universitaria Ospedali Riuniti

Also Known As

Alesiani, Francesco, F Alesiani, F. Alesiani, Francesco Alesiani, J M Hernández-Rivas

Publications

696

Citations

H-Index

Concepts

All Affiliations

Azienda Ospedaliero Universitaria Ospedali Riuniti Marche Polytechnic University Ospedali Riuniti di Ancona Global Earthquake Model L'organizzazione Ospedale di Civitanova M

About

Francesco Alesiani is an author at Azienda Ospedaliero Universitaria Ospedali Riuniti specializing in hematology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	352
2	Health Sciences	4	4	176
3	Engineering	2	2	99
4	Public Health	1	1	11
5	Cell Biology	1	1	100

Francesco Alesiani

Publications

621

Citations

H-Index

Page 1

	Year	Citations
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type‐2 Maria Beatrice Morelli, Massimo Offidani, Francesco Alesiani, International Journal of Cancer Cannabis UseMolecular PharmacologyHematological MalignancyOncologyMedicine	2013	100
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Massimo Offidani, Laura Corvatta, Monica Marconi, PubMed ImmunologyPathologyPharmacotherapyImmunotherapyMyeloid Neoplasia	2006	78
Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA Attilio Olivieri, Guido Gini, Caterina Bocci, The Oncologist	2012	62
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study Massimo Offidani, Laura Corvatta, Laura Maracci, Blood Cancer Journal Hematological MalignancyOncologyHealth SciencesMalignant Blood DisorderHematology	2013	61
PDEBENCH: An Extensive Benchmark for Scientific Machine Learning Makoto Takamoto, Timothy Praditia, Raphael Leiteritz, arXiv (Cornell University) EngineeringMachine LearningMachine Learning ToolExtensive BenchmarkData Science	2022	56
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: A pilot study Giuseppe Visani, Felicetto Ferrara, Francesco Alesiani, Leukemia & lymphoma/Leukemia and lymphoma	2008	50
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma Massimo Offidani, Claudia Polloni, Federica Cavallo, Leukemia & lymphoma/Leukemia and lymphoma Relapsed/refractory PatientsOral PanobinostatRelapsed/refractory MmPathologyPhase Ii Study	2012	44
Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry Massimo Offidani, Laura Corvatta, Claudia Polloni, Clinical Lymphoma Myeloma & Leukemia ReliabilityPrognostic EvaluationHematological MalignancyEngineeringVulnerability Measures	2012	43
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide Massimo Offidani, Laura Corvatta, Claudia Polloni, Leukemia & lymphoma/Leukemia and lymphoma ImmunodeficienciesPrimary Antibiotic ProphylaxisPharmacotherapyThalidomide CombinationsAntimicrobial Chemotherapy	2011	30
Thalidomide‐dexamethasone <i>versus</i> Interferon‐alpha‐dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study Massimo Offidani, Laura Corvatta, Claudia Polloni, British Journal of Haematology Hematological MalignancyConventional ThalidomideMaintenance TreatmentMedicineThadd Induction	2008	28

Page 1